Pancef (Cefixime) is a systemic antimicrobial agent that is commonly used to help manage the conditions resulting from susceptible bacterial infections. It is relevant for use in conditions falling within established therapeutic domains and may assist in easing symptoms related to physical discomfort across several key therapeutic areas.

---

Support for Acute Infections and Symptom Management

This medication provides support for acute respiratory and ear/throat infections, addressing bacterial otitis media, pharyngitis, and acute flare-ups of chronic bronchitis. Its benefit is centered on managing symptoms related to the presence of susceptible bacteria, assisting in easing localized physical discomfort and systemic manifestations like fever. It is also applied in uncomplicated urinary and genital tract issues, such as UTIs and gonorrhea, where it manages the symptom clusters that interfere with comfort, like burning pain and frequency associated with urination. Furthermore, Pancef plays a role in managing specific systemic bacterial illnesses including Typhoid fever and Shigella infections, supporting patients during episodes of heightened discomfort.

---

Quick Fact: Supportive Symptom Relief Context
Pancef is considered relevant when symptomatic assistance is needed to ease physical discomfort and functional strain caused by bacterial infections in the respiratory and urinary tracts.

Who can and cannot use Pancef?

The population eligibility for Pancef (Cefixime) is strictly defined by regulatory documents based on allergy status, age, and organ function.

Contraindicated Populations	Eligibility Status
Known allergy to Cefixime or other Cephalosporin Antibiotics	Absolute Contraindication
Known allergy to any of the product's Excipients	Absolute Contraindication

---

Age-Related Eligibility

The drug is approved for use in adults and pediatric patients six months of age or older. The safety and effectiveness of Pancef in infants aged less than six months have not been established according to FDA labeling [Source 1.8]. While older adults may receive the same dose as younger adults, renal function should be assessed [Source 1.4].

Condition-Based Restrictions

Official labeling requires conditional use for patients with impaired renal function. Dose adjustment is required when creatinine clearance is less than mathbf60 mL/min [Source 1.8]. For patients with severe renal impairment (CrCl leq mathbf20 mL/min), a dose of 200 mg once daily should not be exceeded [Source 1.3]. Additionally, patients with a history of penicillin allergy should use the medicine with caution [Source 1.3].

Pregnancy and Lactation Status

Cefixime should be used during pregnancy only if clearly needed [Source 1.6]. For nursing mothers, consideration should be given to discontinuing nursing temporarily during treatment [Source 1.4].

Interactions with other medicines and products

Pancef (Cefixime) is documented to interact with specific medicinal products, primarily impacting the efficacy or plasma levels of the co-administered substance. The co-administration with coumarin-type anticoagulants, such such as Warfarin, is officially associated with an increased prothrombin time and the risk of clinical bleeding, indicating enhanced effects of the anticoagulant. This clinically significant interaction is noted to pose a higher risk in patients with underlying renal impairment or hepatic impairment.

Interactions also extend to the efficacy of other products. Combinations with Live Bacterial Vaccines (e.g., Typhoid Vaccine, Live; BCG Vaccine Live) are classified as severely significant or contraindicated, as Cefixime may decrease the therapeutic effect of the vaccine through pharmacodynamic antagonism. Administration of the vaccine is typically avoided during and for several days after Cefixime therapy. Furthermore, Cefixime may reduce the effectiveness of oral hormonal contraceptives by altering intestinal flora.

Specific interacting medicines include Carbamazepine, whose elevated plasma levels have been reported when Cefixime is administered concomitantly, a scenario that necessitates drug monitoring. The drug Probenecid is expected to increase Cefixime concentration by inhibiting renal tubular secretion. Regarding the official regulatory profile, Cefixime is not identified as a clinically significant inhibitor or inducer of major Cytochrome P450 enzymes. Lastly, the ingestion of food modifies the rate of absorption of the oral tablet and capsule forms, resulting in an increase in the time to maximal plasma concentration (T max).

Targeting Penicillin-Binding Proteins (PBPs) for Irreversible Inhibition

The core mechanism involves its action as an irreversible inhibitor of Penicillin-Binding Proteins (PBPs), particularly PBP-3. Cefixime acts as a structural mimic of the PBP substrate, forming a strong covalent bond with the enzyme's active site. This targeted molecular action immediately blocks the final transpeptidation step required to cross-link peptidoglycan strands, the polymer providing structural strength to the bacterial cell wall.

The Cascade: Loss of Osmotic Integrity and Cell Lysis

Disruption of peptidoglycan synthesis prevents the bacteria from assembling a rigid, protective cell wall. This defective structure is unable to counter the high internal osmotic pressure within the cell. This pressure imbalance leads to the rapid swelling and eventual rupture (lysis) of the entire bacterial cell. The collective, active destruction of the susceptible bacterial population through cell lysis constitutes the drug's definitive bactericidal effect.

Constraints on the Mechanism: Bacterial Resistance

The bactericidal mechanism is subject to specific biological constraints, notably the presence of bacterial defense systems. Mechanisms such as the production of certain Extended-Spectrum beta-Lactamases (ESBLs) can hydrolyze and inactivate the Cefixime molecule before it reaches its PBP target. Furthermore, genetic alterations in the PBPs themselves (mutated PBPs) can reduce the drug's binding affinity, functionally overcoming the inhibition required for cell lysis.

How Pancef (Cefixime) is Used: Administration Guidelines

Pancef is administered exclusively by the oral route, with dosage forms including film-coated tablets, capsules, and an oral suspension. The medicine is designed for systemic use and may be taken with or without food.

---

Standard Dosage and Frequency

Classification	Guideline
Standard Adult Dose	400 mg daily
Alternative Regimen	200 mg given in two divided doses every 12 hours
Specific Single Dose	400 mg as a single oral dose for uncomplicated gonococcal infections

The standard adult course generally employs the 400 mg daily dose, which can be administered either once or in two divided doses. For specific infections caused by Streptococcus pyogenes, guidelines mandate a minimum treatment duration of at least 10 days.

---

Administration for Specific Populations

Dosage instructions are modified for certain patient groups:

• Pediatric Use: For children 6 months and older, the dose is weight-based, typically 8 mg/kg of body weight per day. The dose may be administered once daily or divided into two 4 mg/kg doses every 12 hours.
• Renal Impairment: For adults with severe renal impairment (creatinine clearance le 20 mL/min), the daily dose must not exceed 200 mg once daily, a rule which also applies to patients undergoing chronic peritoneal dialysis or hemodialysis.

---

Form-Specific Handling

When using the oral suspension, it must be properly shaken well before each dose, and the volume must be accurately measured using a calibrated device. The 400 mg tablets are scored and may be split for administration of the 200 mg dose.

Research Evidence / Overview of Studies for Pancef (Cefixime)

The official research record for Cefixime, the active ingredient in Pancef, includes controlled clinical evaluations and scientific reviews. Research has primarily explored the patterns observed in short-term studies for specific bacterial infections. This overview focuses on the types of studies conducted, the outcomes measured, and the limitations noted in the scientific literature.

Evidence for Acute Respiratory and Ear Infections

Research has extensively evaluated Cefixime using Randomized Controlled Trials (RCTs) in patients experiencing acute or disruptive episodes of acute bacterial otitis media (ear infection) and bacterial pharyngitis/tonsillitis (throat infection). The research describes these trials as primarily used in pediatric patients. Studies monitored two key outcomes describing episodic or acute changes: clinical resolution and the bacteriological eradication of the responsible organisms. Findings describe patterns observed in the studies, including measurements related to the frequency of bacteriological clearance for the targeted pathogens.

Evidence for Uncomplicated Urinary Tract Infections (UTIs)

Cefixime was studied for use in managing uncomplicated lower urinary tract infections (UTIs). The research examined outcomes related to inflammatory or irritative states, focusing heavily on microbiological eradication (clearing bacteria from the urine) and the resolution of symptoms. Data show patterns related to high rates of microbiological eradication in the populations observed. Scientific literature notes that the applicability of historical evidence is impacted by evolving antimicrobial resistance patterns.

What Remains Uncertain and Research Gaps

One area of uncertainty relates to antimicrobial resistance. As bacteria continuously evolve, research must track how resistance patterns affect the applicability of historical evidence. The certainty remains low regarding outcomes when tested against new, multidrug-resistant organisms. The evidence base for long-term outcomes, including data for long-term recurrence rates, is limited. The results apply only to the populations studied and research does not determine whether an individual will have a similar outcome.

Key Studies & References

1. Summary of Product Characteristics - Cefixime FrostPharma 20 mg/ ml granules for oral suspension (Comprehensive regulatory summary including pediatric and renal dosing considerations)
2. Clinical Effectiveness and Safety of Cefixime in Managing Typhoid Fever in Indian Population: A Real-world Evidence Study (Evidence for systemic infection and special population/geographic context)
3. Cefixime: MedlinePlus Drug Information (Authoritative patient information summary)

Common questions about Pancef (FAQ)

Q: Does Pancef work for viral infections?

Pancef (cefixime) is an antibiotic designed to treat specific infections caused by susceptible bacteria. Regulatory documents indicate that antibiotics are not effective against infections caused by viruses, such as the common cold or flu.

Q: How quickly should I expect to feel better after starting Pancef?

Official product information states that improvement in symptoms is generally expected during the first few days of treatment with cefixime.

Q: Is it necessary to finish the entire course of Pancef even if symptoms improve quickly?

Official sources describe the principle of completing the full prescribed course of an antibiotic. The guidance notes that stopping treatment too soon, even if symptoms improve, may prevent the infection from being completely treated and could increase the risk of antibiotic resistance.

Q: Is Pancef safe for children?

Official regulatory documents indicate that the drug is approved for use in pediatric patients six months of age and older. The safety and effectiveness of the drug have not been established for children younger than six months old.

Q: What happens if a dose of Pancef is missed?

Official regulatory guidance describes instructions for a missed dose, generally stating that a patient may take the dose as soon as they remember, or skip it if it is almost time for the next dose. The guidance advises against doubling the dose.

Q: What is the typical duration of treatment with Pancef?

The official duration guidelines for treatment with Pancef (cefixime) typically range from 7 to 10 days. The full course may be extended up to 14 days, which is determined by a healthcare professional based on the specific infection being treated.

Q: Can Pancef be crushed or split if a person has trouble swallowing pills?

This depends on the specific form of the medicine. The tablet form may be scored, allowing it to be split if a smaller dose is prescribed. However, the capsule formulation is designed to be swallowed whole and is not intended to be cut, broken, or chewed according to official labeling.

Q: Do official documents mention a maximum duration of treatment for Pancef?

Official guidance from regulatory agencies addresses the duration of treatment, stating that the typical course may be continued for a maximum of up to 14 days.

Q: How does taking Pancef affect the gut microbiome?

As a broad-spectrum antibiotic, Pancef’s use can alter the normal balance of bacteria in the colon. Regulatory documents note that this alteration may lead to the overgrowth of Clostridium difficile bacteria, which is associated with severe diarrhea.

Q: How long does Pancef stay in the body after the last dose?

In adults with normal kidney function, the serum elimination half-life is typically 3 to 4 hours. Approximately 50% of the absorbed dose is removed from the body via urine within 24 hours.

Q: Why is Pancef sometimes described as a 'third-generation' medication?

Cefixime is officially classified as a 'third-generation' cephalosporin. This classification is a grouping system used to describe the drug's spectrum of activity, particularly its distinct spectrum of activity that includes specific types of Gram-negative bacteria.

Q: Is Pancef known to cause changes in blood sugar levels?

Official documentation indicates that Pancef (cefixime) can cause unusual laboratory results with certain tests that measure sugar (glucose) in the urine. This is considered an interference with the test itself and does not necessarily indicate a change in a person's actual blood sugar levels.

Q: Does Pancef cause temporary discoloration of urine?

Dark urine is listed in adverse reaction reports as a less common side effect. It is associated with potential hepatic (liver) issues, such as jaundice.

Q: How is the potency of Pancef measured or described?

The drug's potency and its effectiveness against specific bacterial strains are formally measured and described using Minimum Inhibitory Concentration (MIC) susceptibility data, which is detailed in the microbiology section of the official label.

Q: Can Pancef be used for preventative measures before surgery?

Official labeling indicates Pancef for the treatment of specific infections caused by susceptible bacteria, such as otitis media and uncomplicated urinary tract infections. It is not explicitly indicated for general surgical prophylaxis (prevention).

Q: Does Pancef require any special dietary considerations?

Official guidance states that Pancef is typically taken with or without food. A normal diet may be continued unless a healthcare professional specifically advises otherwise.

Q: Why is it important to know who cannot use Pancef?

Official regulatory documents define strict contraindications for the medication due to the potential risk of severe, potentially fatal, allergic reactions, such as anaphylaxis, in patients with a history of allergy to cefixime or other cephalosporin antibiotics.

Q: Is feeling more tired than usual a normal experience while on Pancef?

Reports indicate that general tiredness or weakness is listed as a less common adverse reaction in clinical trials. If this symptom is severe or concerning, a healthcare professional should be consulted.

The storage and disposal of Pancef (Cefixime) must adhere strictly to the conditions specified in the official labeling. The dry product (tablets and powder) should be stored at controlled room temperature, typically 20 C to 25 C, and must be kept in its original container with the lid tightly closed to protect it from moisture. All formulations must be kept out of the reach of children.

---

Stability and Disposal

Once the oral suspension is prepared, it remains stable for 14 days and must not be frozen; any unused portion after this time must be discarded. Regarding disposal, unused or expired Pancef should not be flushed down a toilet or poured into a drain. It must be discarded using a formal drug take-back program or by following local government disposal guidelines.